Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
An LRP1-binding motif in cellular prion protein replicates cell-signaling activities of the full-length protein
Elisabetta Mantuano, Carlotta Zampieri, Pardis Azmoon, Cory B. Gunner, Kyle R. Heye, Steven L. Gonias
Elisabetta Mantuano, Carlotta Zampieri, Pardis Azmoon, Cory B. Gunner, Kyle R. Heye, Steven L. Gonias
View: Text | PDF
Research Article Cell biology Inflammation

An LRP1-binding motif in cellular prion protein replicates cell-signaling activities of the full-length protein

  • Text
  • PDF
Abstract

Low-density lipoprotein receptor-related protein-1 (LRP1) functions as a receptor for nonpathogenic cellular prion protein (PrPC), which is released from cells by ADAM (a disintegrin and metalloproteinase domain) proteases or in extracellular vesicles. This interaction activates cell signaling and attenuates inflammatory responses. We screened 14-mer PrPC-derived peptides and identified a putative LRP1 recognition motif in the PrPC sequence spanning residues 98–111. A synthetic peptide (P3) corresponding to this region replicated the cell-signaling and biological activities of full-length shed PrPC. P3 blocked LPS-elicited cytokine expression in macrophages and microglia and rescued the heightened sensitivity to LPS in mice in which the PrPC gene (Prnp) had been deleted. P3 activated ERK1/2 and induced neurite outgrowth in PC12 cells. The response to P3 required LRP1 and the NMDA receptor and was blocked by the PrPC-specific antibody, POM2. P3 has Lys residues, which are typically necessary for LRP1 binding. Converting Lys100 and Lys103 into Ala eliminated the activity of P3, suggesting that these residues are essential in the LRP1-binding motif. A P3 derivative in which Lys105 and Lys109 were converted into Ala retained activity. We conclude that the biological activities of shed PrPC, attributed to interaction with LRP1, are retained in synthetic peptides, which may be templates for therapeutics development.

Authors

Elisabetta Mantuano, Carlotta Zampieri, Pardis Azmoon, Cory B. Gunner, Kyle R. Heye, Steven L. Gonias

×

Figure 10

P3 rescues the increased susceptibility of Prnp–/– mice to LPS.

Options: View larger image (or click on image) Download as PowerPoint
P3 rescues the increased susceptibility of Prnp–/– mice to LPS.
Male 16-...
Male 16- to 20-week old Prnp–/– mice (shown in orange) and wild-type mice in the same genetic background (shown in black) were challenged with LPS, by IP injection, at 75% of the LD50. A second matched cohort of Prnp–/– mice was treated with LPS and then with P3, 0.5 hour later (blue). Toxicity was scored as described in Methods. Prnp–/– mice demonstrated significantly more toxicity compared with wild-type mice (mean ± SEM; n = 4; 2-way ANOVA: *P < 0.05; ***P < 0.001; ****P < 0.0001). P3 significantly reversed the toxicity of LPS in Prnp–/– mice (mean ± SEM; n = 4; 2-way ANOVA: †P < 0.05; †††P < 0.001; ††††P < 0.0001). MSS, mouse sepsis score.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts